{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:34:17Z","timestamp":1768732457426,"version":"3.49.0"},"reference-count":104,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/mjt.0b013e3181df8e1b","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T12:21:10Z","timestamp":1276863670000},"page":"418-439","source":"Crossref","is-referenced-by-count":34,"title":["Fibromyalgia Syndrome: A Discussion of the Syndrome and Pharmacotherapy"],"prefix":"10.1097","volume":"17","author":[{"given":"Howard S","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Barkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780380104","article-title":"The prevalence and characteristics of fibromylagia in the general population.","volume":"38","author":"Wolfe","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R2-10-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/rheumatology\/37.5.555","article-title":"National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis.","volume":"37","author":"Miedema","year":"1998","journal-title":"Br J Rheumatol"},{"key":"R3-10-20210202","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar2005","article-title":"Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome.","volume":"8","author":"Buskila","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R4-10-20210202","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/art.20042","article-title":"Family study of fibromyalgia.","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R5-10-20210202","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/art.10103","article-title":"Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety related personality traits.","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R6-10-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10067-002-8284-5","article-title":"Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients.","volume":"21","author":"Gursoy","year":"2002","journal-title":"Clin Rheumatol"},{"key":"R7-10-20210202","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00296-002-0260-5","article-title":"Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.","volume":"23","author":"Gursoy","year":"2003","journal-title":"Rheumatol Int"},{"key":"R8-10-20210202","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.mp.4001568","article-title":"An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship personality traits.","volume":"9","author":"Buskila","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R9-10-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2474-8-27","article-title":"An internet survey of 2,596 people with fibromyalgia.","volume":"8","author":"Bennett","year":"2007","journal-title":"BMC Musculoskelet Disord"},{"key":"R10-10-20210202","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.whi.2008.04.005","article-title":"Self-assessed physical function levels of women with fibromyalgia: a national survey.","volume":"18","author":"Jones","year":"2008","journal-title":"Womens Health Issues"},{"key":"R11-10-20210202","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/ard.60.11.1040","article-title":"The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.","volume":"60","author":"Carmona","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R12-10-20210202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1529-0131(200002)13:1<42::AID-ART7>3.0.CO;2-R","article-title":"Quality of life issues for fibromyalgia patients.","volume":"13","author":"Bernard","year":"2000","journal-title":"Arthritis Care Res"},{"key":"R13-10-20210202","first-page":"475","article-title":"Fibromyalgia and quality of life: a comparative analysis.","volume":"20","author":"Burckhardt","year":"1993","journal-title":"J Rheumatol"},{"key":"R14-10-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R15-10-20210202","first-page":"6","article-title":"Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.","volume":"75","author":"Mease","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"R16-10-20210202","first-page":"663","article-title":"Sexual dysfunction in fibromyalgia patients.","volume":"26","author":"Orellana","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R17-10-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10067-009-1093-3","article-title":"Association between fibromyalgia and sexual dysfunction in women.","volume":"28","author":"Kalichman","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R19-10-20210202","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00045391-200305000-00005","article-title":"Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome.","volume":"10","author":"McCarberg","year":"2003","journal-title":"Am J Ther"},{"key":"R20-10-20210202","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R22-10-20210202","first-page":"555","article-title":"Sexual functioning of women with fibromyalgia.","volume":"24","author":"Prins","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R23-10-20210202","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/jwh.2006.15.1035","article-title":"Womens health issues with fibromyalgia syndrome.","volume":"15","author":"Shaver","year":"2006","journal-title":"J Womens Health (Larchmt)"},{"key":"R24-10-20210202","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1743-6109.2009.01490.x","article-title":"Musculoskeletal pain and sexual function in women.","volume":"7","author":"Rosenbaum","year":"2010","journal-title":"J Sex Med"},{"key":"R25-10-20210202","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11926-009-0064-7","article-title":"Sexual dysfunction in patients with fibromyalgia.","volume":"11","author":"Orellana","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"R26-10-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0304-3959(88)90019-X","article-title":"Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.","volume":"32","author":"Vaeroy","year":"1988","journal-title":"Pain"},{"key":"R27-10-20210202","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/art.1780371106","article-title":"Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome.","volume":"37","author":"Russell","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R28-10-20210202","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0196-9781(00)00219-9","article-title":"A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid.","volume":"21","author":"Liu","year":"2000","journal-title":"Peptides"},{"key":"R29-10-20210202","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/1529-0131(199912)42:12<2731::AID-ANR36>3.0.CO;2-K","article-title":"Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia?","volume":"42","author":"Bradley","year":"1999","journal-title":"Arthris Rheum"},{"key":"R30-10-20210202","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis.","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R31-10-20210202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jpain.2007.05.002","article-title":"Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome.","volume":"8","author":"Sarchielli","year":"2007","journal-title":"J Pain"},{"key":"R32-10-20210202","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/ar2783","article-title":"The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties.","volume":"11","author":"Bennett","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R33-10-20210202","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jama.2008.944","article-title":"Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis.","volume":"301","author":"Hauser","year":"2009","journal-title":"JAMA"},{"key":"R36-10-20210202","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1111\/j.1526-4637.2006.00178.x","article-title":"Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.","volume":"8","author":"Arnold","year":"2007","journal-title":"Pain Med"},{"key":"R37-10-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.mjt.0000134786.50087.d8","article-title":"A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions.","volume":"12","author":"Beebe","year":"2005","journal-title":"Am J Ther"},{"key":"R38-10-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00045391-200403000-00010","article-title":"Anticholinergic syndrome after anesthesia: a case report and review.","volume":"11","author":"Brown","year":"2004","journal-title":"Am J Ther"},{"key":"R39-10-20210202","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MJT.0b013e31815b035b","article-title":"Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic\/persistent pain.","volume":"15","author":"Barkin","year":"2008","journal-title":"Am J Ther"},{"key":"R40-10-20210202","first-page":"8","article-title":"Duloxetine: A pharmacological overview.","volume":"22","author":"Barkin","year":"2007","journal-title":"Pain Medicine Network"},{"key":"R41-10-20210202","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R42-10-20210202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"key":"R43-10-20210202","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"key":"R44-10-20210202","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJGM.S3979","article-title":"A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.","volume":"1","author":"Chappell","year":"2008","journal-title":"International Journal of General Medicine"},{"key":"R45-10-20210202","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4088\/PCC.08m00680","article-title":"Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.","volume":"11","author":"Arnold","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R46-10-20210202","first-page":"8","article-title":"Milnacipran: a pharmacotherapeutic-focused brief review.","volume":"23","author":"Barkin","year":"2009","journal-title":"Pain Medicine Network"},{"key":"R47-10-20210202","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.","volume":"19","author":"Vitton","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"R48-10-20210202","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.","volume":"30","author":"Clauw","year":"2008","journal-title":"Clin Ther"},{"key":"R49-10-20210202","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia, a randomized, double-blind, placebo-controlled trial.","volume":"36","author":"Mease","year":"2009","journal-title":"J Rheumatol"},{"key":"R50-10-20210202","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","article-title":"Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Pain Med"},{"key":"R51-10-20210202","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11202810-000000000-00000","article-title":"Milnacipran: in fibromyalgia.","volume":"70","author":"Chwieduk","year":"2010","journal-title":"Drugs"},{"key":"R52-10-20210202","first-page":"1423","article-title":"Milnacipran improves fatigue in fibromyalgia: pooled analyses from 3 randomized, placebo-controlled clinical Trials [Abstract].","volume":"60","author":"Mease","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R53-10-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Research"},{"key":"R54-10-20210202","first-page":"8","article-title":"Pregabalin: a critical review.","volume":"24","author":"Barkin","year":"2008","journal-title":"Pain Medicine Network"},{"key":"R55-10-20210202","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2146\/ajhp060371","article-title":"Pregabalin: an antiepileptic agent useful for neuropathic pain.","volume":"64","author":"Blommel","year":"2007","journal-title":"American Journal of Health-System Pharmacy"},{"key":"R56-10-20210202","first-page":"4","article-title":"Methadone: a novel and potentially hazardous opioid analgesic.","volume":"21","author":"Barkin","year":"2006","journal-title":"Pain Medicine Network"},{"key":"R58-10-20210202","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo controlled trial.","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R59-10-20210202","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"R60-10-20210202","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"R61-10-20210202","first-page":"S256","article-title":"Pregabalin for management of fibromyalgia (FM): a 14-week, randomized, double-blind, placebo-controlled monotherapy trial (study A0081100).","volume":"67","author":"Pauer","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R62-10-20210202","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","article-title":"Treatment of fibromyalgia syndrome with gabapentin and pregabalin-a meta-analysis of randomized controlled trials.","volume":"145","author":"Hauser","year":"2009","journal-title":"Pain"},{"key":"R63-10-20210202","first-page":"8","article-title":"Tapentadol: a pharmacotherapeutic-focused brief review.","volume":"24","author":"Barkin","year":"2009","journal-title":"Pain Medicine Network"},{"key":"R64-10-20210202","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1213\/ane.0b013e31818881ca","article-title":"Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.","volume":"107","author":"Kleinert","year":"2008","journal-title":"Anesth Analg"},{"key":"R65-10-20210202","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1185\/03007990902728183","article-title":"A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain.","volume":"25","author":"Daniels","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R66-10-20210202","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1185\/03007990902816970","article-title":"Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.","volume":"25","author":"Hale","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R67-10-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.36076\/ppj.2010\/13\/61","article-title":"Dose conversion between tapentadol immediate and extended release for low back pain.","volume":"13","author":"Etropolski","year":"2010","journal-title":"Pain Physician"},{"key":"R68-10-20210202","first-page":"145","article-title":"Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review.","volume":"14","author":"Sloan","year":"2008","journal-title":"J Opioid Manage"},{"key":"R69-10-20210202","first-page":"6","article-title":"Drug metabolism.","volume":"22","author":"Barkin","year":"2007","journal-title":"Pain Medicine Network"},{"key":"R70-10-20210202","first-page":"4","article-title":"Incorporation of science and clinical medicine in the process of patient-specific and patient-centered, patient focused prescribing and personalized patient care.","volume":"23","author":"Barkin","year":"2008","journal-title":"Pain Medicine Network"},{"key":"R71-10-20210202","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/00002508-200207001-00009","article-title":"Role of urine toxicology testing in the management of chronic opioid therapy.","volume":"18","author":"Katz","year":"2002","journal-title":"Clin J Pain"},{"key":"R72-10-20210202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.rdc.2009.05.004","article-title":"Exercise interventions in fibromyalgia: clinical applications from the evidence.","volume":"35","author":"Jones","year":"2009","journal-title":"Rheum Dis Clin N Am"},{"key":"R73-10-20210202","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/acm.2008.0050","article-title":"Six weeks of whole-body vibration exercise improves pain and fatigue in women with fibromyalgia.","volume":"14","author":"Alentorn-Geli","year":"2008","journal-title":"J Altern Complement Med"},{"key":"R74-10-20210202","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1089\/acm.2007.0615","article-title":"Effects of yoga and the addition of Tui Na in patients with fibromyalgia.","volume":"13","author":"da Silva","year":"2007","journal-title":"J Altern Complement Med"},{"key":"R75-10-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00296-008-0644-2","article-title":"Thalassotherapy for fibromyalgia: a randomized controlled trial comparing aquatic exercises in sea water and water pool.","volume":"29","author":"de Andrade","year":"2008","journal-title":"Rheumatol Int"},{"key":"R76-10-20210202","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00296-008-0538-3","article-title":"Effectiveness of aquatic therapy in the treatment of fibromyalgia syndrome: a randomized controlled open study.","volume":"28","author":"Evcik","year":"2008","journal-title":"Rheumatol Int"},{"key":"R77-10-20210202","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1475-097X.2007.00776.x","article-title":"Resistance exercise training improves heart rate variability in women with fibromyalgia.","volume":"28","author":"Figueroa","year":"2008","journal-title":"Clin Physiol Funct Imaging"},{"key":"R78-10-20210202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1300\/J094v15n01_02","article-title":"Effects of lifestyle physical activity on health status, pain, and function in adults with fibromyalgia syndrome.","volume":"15","author":"Fontaine","year":"2007","journal-title":"J Muscoskel Pain"},{"key":"R79-10-20210202","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/ar2377","article-title":"Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial [Abstract].","volume":"10","author":"Gusi","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"R80-10-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/09638280701400540","article-title":"The effect of Qigong on fibromyalgia (FMS): a controlled randomized study.","volume":"30","author":"Haak","year":"2008","journal-title":"Disabil Rehabil"},{"key":"R81-10-20210202","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.23203","article-title":"A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia.","volume":"58","author":"Jones","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R82-10-20210202","first-page":"532","article-title":"Effectiveness of physical exercise on decrease of pain in patients with fibromyalgia [Abstract].","volume":"56","author":"Kayo","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R83-10-20210202","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2340\/16501977-0409","article-title":"Pool exercise produces therapeutic effects in patients with fibromyalgia or chronic widespread pain.","volume":"41","author":"Mannerkorpi","year":"2009","journal-title":"J Rehabil Med"},{"key":"R84-10-20210202","first-page":"410","article-title":"Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia.","volume":"25","author":"Matsutani","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R85-10-20210202","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.apmr.2008.03.026","article-title":"Assessment of the effects of aquatic therapy on global symptomatology in patients with fibromyalgia syndrome: a randomized controlled trial.","volume":"89","author":"Munguia-Izquierdo","year":"2008","journal-title":"Arch Phys Med Rehabil"},{"key":"R86-10-20210202","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1001\/archinte.167.20.2192","article-title":"Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial.","volume":"167","author":"Rooks","year":"2007","journal-title":"Arch Intern Med"},{"key":"R87-10-20210202","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.24115","article-title":"Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial.","volume":"59","author":"Stephens","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R88-10-20210202","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1249\/01.mss.0b0138059aec4","article-title":"Aquatic training and detraining on fitness and quality of life in fibromyalgia.","volume":"39","author":"Tomas-Carus","year":"2007","journal-title":"Med Sci Sports Exerc"},{"key":"R89-10-20210202","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2340\/16501977-0168","article-title":"Eight months of physical training in warm water improves physical and mental health in women with fibromyalgia: a randomized controlled trial.","volume":"40","author":"Tomas-Carus","year":"2008","journal-title":"J Rehabil Med"},{"key":"R90-10-20210202","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.apmr.2008.01.022","article-title":"Effects of concurrent strength and endurance training on physical fitness and symptoms in postmenopausal women with fibromyalgia: a randomized controlled trial.","volume":"89","author":"Valkeinen","year":"2008","journal-title":"Arch Phys Med Rehabil"},{"key":"R91-10-20210202","first-page":"582","article-title":"High or low intensity aerobic fitness training in fibromyalgia: does it matter?","volume":"29","author":"van Santen","year":"2002","journal-title":"J Rheumatol"},{"key":"R92-10-20210202","first-page":"1041","article-title":"A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia.","volume":"29","author":"Jones","year":"2002","journal-title":"J Rheumatol"},{"key":"R93-10-20210202","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.apmr.2005.04.014","article-title":"The effects of a 12-week strength-training program on strength and functionality in women with fibromyalgia.","volume":"86","author":"Kingsley","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"key":"R94-10-20210202","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00296-007-0484-5","article-title":"Effects of muscle strengthening versus aerobic exercise program in fibromyalgia.","volume":"28","author":"Bircan","year":"2008","journal-title":"Rheumatol Int"},{"key":"R95-10-20210202","first-page":"1287","article-title":"Effects of strength training on muscle strength, cross-sectional area, maximal electromyographic activity, and serum hormones in premenopausal women with fibromyalgia.","volume":"29","author":"Hakkinen","year":"2002","journal-title":"J Rheumatol"},{"key":"R96-10-20210202","first-page":"34","article-title":"Effects of prolonged vs muscle strengthen programs on fibromyalgia [Abstract].","volume":"70","author":"Hannonen","year":"1995","journal-title":"J Muscoskel Pain"},{"key":"R97-10-20210202","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/03009740510018697","article-title":"Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia.","volume":"34","author":"Valkeinen","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"R98-10-20210202","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/art.21751","article-title":"Acute heavy-resistance exercise induced pain and neuromuscular fatigue in elderly women with fibromyalgia and in healthy controls: effects of strength training.","volume":"54","author":"Valkeinen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R99-10-20210202","first-page":"1050","article-title":"An exercise program in the treatment of fibromyalgia.","volume":"23","author":"Martin","year":"1996","journal-title":"J Rheumatol"},{"key":"R100-10-20210202","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.1780310908","article-title":"A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia.","volume":"31","author":"McCain","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R101-10-20210202","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/bmj.325.7357.185","article-title":"Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial.","volume":"325","author":"Richards","year":"2002","journal-title":"BMJ"},{"key":"R102-10-20210202","first-page":"1060","article-title":"Aerobic fitness effects in fibromyalgia.","volume":"30","author":"Valim","year":"2003","journal-title":"J Rheumatol"},{"key":"R103-10-20210202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1964.01720240015003","article-title":"Thinking and depression: theory and therapy.","volume":"10","author":"Beck","year":"1964","journal-title":"Arch Gen Psychiatry"},{"key":"R104-10-20210202","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/ar2010","article-title":"Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments.","volume":"8","author":"Thieme","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R105-10-20210202","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.comppsych.2009.01.008","article-title":"Brief cognitive-behavioral therapy with fibromyalgia patients in routine care.","volume":"50","author":"Vazquez-Rivera","year":"2009","journal-title":"Compr Pstchiatry"},{"key":"R106-10-20210202","first-page":"1280","article-title":"Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention.","volume":"29","author":"Williams","year":"2002","journal-title":"J Rheumatol"},{"key":"R107-10-20210202","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/archinte.166.14.1512","article-title":"Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial.","volume":"166","author":"Allen","year":"2006","journal-title":"Arch Intern Med"},{"key":"R109-10-20210202","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","article-title":"EULAR evidence-based recommendations for the management of fibromylagia syndrome.","volume":"67","author":"Carville","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R110-10-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00482-008-0673-5","article-title":"General principles of therapy, coordination of medical care and patient education in fibromyalgia syndrome and chronic widespread pain [in German].","volume":"22","author":"Klement","year":"2008","journal-title":"Schmerz"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201007000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T02:30:59Z","timestamp":1740191459000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201007000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181df8e1b","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}